RET fusion gene: translation to personalized lung cancer therapy
about
Gene aberrations for precision medicine against lung adenocarcinomaCurrent and future molecular profiling of cancer by next-generation sequencingBeyond ALK-RET, ROS1 and other oncogene fusions in lung cancerPromising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLCEGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression.Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's PerspectiveChromatin-regulating proteins as targets for cancer therapy.Recent advances in personalized lung cancer medicineRET-targeting molecular stratified non-small-cell lung cancers.Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyondKAOS: a new automated computational method for the identification of overexpressed genes.Novel kinase fusion transcripts found in endometrial cancerSystemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinomaGene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan.Detecting and targetting oncogenic fusion proteins in the genomic era.The emerging complexity of gene fusions in cancer.Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.Omics Profiling in Precision Oncology.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood.Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET.Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer.Expression of PFKFB3 and Ki67 in lung adenocarcinomas and targeting PFKFB3 as a therapeutic strategy.Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor.The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.Drug resistance profiles of mutations in the RET kinase domain
P2860
Q26749348-A2F95ADA-86C9-4710-A14D-AED2D440F2A3Q26796272-1281AF28-3478-4A58-925C-EDE47A105282Q26851421-D086D4C2-6278-4807-8293-0D565C6CD4B8Q27025970-59143D02-0D5E-49DA-8ED3-0189E4A055D8Q33688972-A66C6E06-51D7-41DA-9471-169CD34FD6C4Q33906921-4648CFE6-56BA-402A-90E1-7D1DBF16D2BFQ33907067-F500A387-8103-4F2A-ADB3-7618BD1B0230Q34678073-C54CA476-1005-4495-BAB6-32F82B4FE63FQ35200445-00039092-FF15-4E91-9516-7E4D4CB81F1FQ35256622-BDC88A20-276B-4696-A965-CEA21CB81715Q36276385-E0BD528B-6BBD-4B63-A22C-D778DA9A4794Q36393068-EBB29D14-E30C-4E96-947C-4DFBE11AC1A1Q37204286-D186FAE2-F7CF-478C-BCEE-B16711C2E5C6Q37392650-6CEA4AB2-6C8D-4BBF-A019-183F6568007AQ37665468-3E85A030-4274-41EE-B247-CDED8F0C6FDBQ37724947-2E09B226-2474-41B6-B3E7-62A3521C376AQ38320914-EBBE21A8-7E5F-4A13-A856-C6E2793D6C11Q38336067-A98C94A4-DA88-4270-B3BE-C4A87BA12956Q38496502-720C26EB-C320-4302-9D2E-21BC0A1CC51FQ38753582-5EE09800-D3A9-4F2C-B7A1-11DC1894EEE3Q38813546-B3D8634A-2E68-4C62-8E47-65A4E7057D51Q39220897-DA15C4FA-EB5F-4353-B4D6-34DCB78E953AQ41708857-663E9C2B-A0E9-4CE1-BD97-A65A07858BBDQ42315652-2636FED2-750F-44BD-ABF6-D516CAAE1237Q47104655-73ADA377-B8E8-46D0-B267-FF71858382ABQ47134008-0440EB62-A341-4A8C-B136-B2619EBA40A5Q47658633-1E5693C7-8281-43D4-84A4-BB1A8B7CF1EAQ48649855-A623C429-FC42-41ED-9703-EF86AB6C2D5BQ50053792-8B117F4D-4758-42C0-9F80-FE2CCCCA85B6Q50085302-358B85A7-2745-4567-9B5F-746C18E9F295Q53031630-5E9A65C8-E4F6-4A83-A44F-CC0D48E5265FQ54312155-08D53A35-9E1E-420A-9A54-24FAFC263942Q58044610-B5CCADAE-D3B7-4019-B162-4A98001BB66D
P2860
RET fusion gene: translation to personalized lung cancer therapy
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
RET fusion gene: translation to personalized lung cancer therapy
@ast
RET fusion gene: translation to personalized lung cancer therapy
@en
type
label
RET fusion gene: translation to personalized lung cancer therapy
@ast
RET fusion gene: translation to personalized lung cancer therapy
@en
prefLabel
RET fusion gene: translation to personalized lung cancer therapy
@ast
RET fusion gene: translation to personalized lung cancer therapy
@en
P2093
P2860
P356
P1433
P1476
RET fusion gene: translation to personalized lung cancer therapy
@en
P2093
Katsuya Tsuchihara
Kiyotaka Yoh
Koichi Goto
Koji Tsuta
Takashi Kohno
Takashi Nakaoku
P2860
P304
P356
10.1111/CAS.12275
P577
2013-10-01T00:00:00Z